Harpreet Kaur, Ph.D.

Scientist
Pro-bono Consultant
Food Blogger

Contact Me

Publications

Scientific journal articles (peer-reviewed)

https://www.ncbi.nlm.nih.gov/myncbi/1L5gP2127iC5l/bibliography/public/

First author (main author) publications

  1. Kaur H, Ali SZ, Huey L, Hütt-Cabezas M, Taylor I, Mao XG, Weingart M, Chu Q, Rodriguez FJ, Eberhart CG, Raabe EH. The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Lett. 2016 Jul 10;377(1):55-64. doi: 10.1016/j.canlet.2016.04.020. Epub 2016 Apr 18. PubMed PMID: 27102002; PubMed Central PMCID: PMC5091648
  2. Kaur H, Hütt-Cabezas M, Weingart MF, Xu J, Kuwahara Y, Erdreich-Epstein A, Weissman BE, Eberhart CG, Raabe EH. The chromatin-modifying protein HMGA2 promotes atypical teratoid/rhabdoid cell tumorigenicity. J Neuropathol Exp Neurol. 2015 Feb;74(2):177-85. doi: 10.1097/NEN.0000000000000161. PubMed PMID: 25575139; PubMed Central PMCID: PMC4695975.
  3. Kaur H, Burden-Gulley SM, Phillips-Mason PJ, Basilion JP, Sloan AE, Brady-Kalnay SM. Protein tyrosine phosphatase mu regulates glioblastoma cell growth and survival in vivo. Neuro Oncol. 2012 May;14(5):561-73. doi: 10.1093/neuonc/nos066. Epub 2012 Apr 14. PubMed PMID: 22505657; PubMed Central PMCID: PMC3337312.
  4. Kaur H, Phillips-Mason PJ, Burden-Gulley SM, Kerstetter-Fogle AE, Basilion JP, Sloan AE, Brady-Kalnay SM. Cadherin-11, a marker of the mesenchymal phenotype, regulates glioblastoma cell migration and survival in vivo. Mol Cancer Res. 2012 Mar;10(3):293-304. doi: 10.1158/1541-7786.MCR-11-0457. Epub 2012 Jan 20. PubMed PMID: 22267545; PubMed Central PMCID: PMC3307867.
  5. Kaur H, Bekier ME, Taylor WR. Regulation of Borealin by phosphorylation at serine 219. J Cell Biochem. 2010 Dec 1;111(5):1291-8. doi: 10.1002/jcb.22853. PubMed PMID: 20803554.
  6. Kaur H, Stiff AC, Date DA, Taylor WR. Analysis of mitotic phosphorylation of borealin. BMC Cell Biol. 2007 Jan 22;8:5. doi: 10.1186/1471-2121-8-5. PubMed PMID: 17241471; PubMed Central PMCID: PMC1794407.
  7. In Process: Targeting pediatric ATRT tumors with the anti-malarial quinacrine, 2021
  8. In Process: HMGA2 promotes tumorigenicity in the pediatric brain tumor DIPG, 2021

Co-author (contributing author) publications

  1. Shahab S, Rubens J, Kaur H, Sweeney H, Eberhart CG, Raabe EH. MEK Inhibition Suppresses Growth of Atypical Teratoid/Rhabdoid Tumors. J Neuropathol Exp Neurol. 2020 Jul 1;79(7):746-753.doi: 10.1093/jnen/nlaa042. PubMed PMID: 32472116; PubMed Central PMCID: PMC7821707.
  2. Hanaford AR, Alt J, Rais R, Wang SZ, Kaur H, Thorek DLJ, Eberhart CG, Slusher BS, Martin AM, Raabe EH. Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. Transl Oncol. 2019 Oct;12(10):1314-1322. doi: 10.1016/j.tranon.2019.05.013. Epub 2019 Jul 21. PubMed PMID: 31340195; PubMed Central PMCID: PMC6657308.
  3. Wang SZ, Poore B, Alt J, Price A, Allen SJ, Hanaford AR, Kaur H, Orr BA, Slusher BS, Eberhart CG, Raabe EH, Rubens JA. Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. Clin Cancer Res. 2019 Oct 1;25(19):5925-5936. doi: 10.1158/1078-0432.CCR-19-0189. Epub 2019 Jul 12. PubMed PMID: 31300448; PubMed Central PMCID: PMC6781869.
  4. Miyahara H, Yadavilli S, Natsumeda M, Rubens JA, Rodgers L, Kambhampati M, Taylor IC, Kaur H,Asnaghi L, Eberhart CG, Warren KE, Nazarian J, Raabe EH. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Lett. 2017 Aug 1;400:110-116. doi: 10.1016/j.canlet.2017.04.019. Epub 2017 Apr 25. PubMed PMID: 28450157; PubMed Central PMCID: PMC5569904.
  5. Natsumeda M, Maitani K, Liu Y, Miyahara H, Kaur H, Chu Q, Zhang H, Kahlert UD, Eberhart CG. Targeting Notch Signaling and Autophagy Increases Cytotoxicity in Glioblastoma Neurospheres. Brain Pathol. 2016 Nov;26(6):713-723. doi: 10.1111/bpa.12343. Epub 2016 Feb 8. PubMed PMID: 26613556.
  6. Asnaghi L, Tripathy A, Yang Q, Kaur H, Hanaford A, Yu W, Eberhart CG. Targeting Notch signaling as a novel therapy for retinoblastoma. Oncotarget. 2016 Oct 25;7(43):70028-70044. doi: 10.18632/oncotarget.12142. PubMed PMID: 27661116; PubMed Central PMCID: PMC5342532.
  7. Glod J, Rahme GJ, Kaur H, H Raabe E, Hwang EI, Israel MA. Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities. J Pediatr Hematol Oncol. 2016 May;38(4):249-60. doi: 10.1097/MPH.0000000000000551. Review. PubMed PMID: 26989915; PubMed Central PMCID: PMC5003110.
  8. Weingart MF, Roth JJ, Hutt-Cabezas M, Busse TM, Kaur H, Price A, Maynard R, Rubens J, Taylor I, Mao XG, Xu J, Kuwahara Y, Allen SJ, Erdreich-Epstein A, Weissman BE, Orr BA, Eberhart CG, Biegel JA, Raabe EH. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget. 2015 Feb 20;6(5):3165-77. doi: 10.18632/oncotarget.3078. PubMed PMID: 25638158; PubMed Central PMCID: PMC4413645.
  9. Phillips-Mason PJ, Kaur H, Burden-Gulley SM, Craig SE, Brady-Kalnay SM. Identification of phospholipase C gamma1 as a protein tyrosine phosphatase mu substrate that regulates cell migration. J Cell Biochem. 2011 Jan;112(1):39-48. doi: 10.1002/jcb.22710. PubMed PMID: 20506511; PubMed Central PMCID: PMC3031780.
  10. Kosik A, Bekier ME, Katusin JD, Kaur H, Zhou X, Diakonova M, Chadee DN, Taylor WR. Investigating the role of Aurora kinases in RAS signaling. J Cell Biochem. 2009 Jan 1;106(1):33-41. doi: 10.1002/jcb.21974. PubMed PMID: 19009561.